Internal Medicine, Hematology & Oncology · Reno, NV
NPI
1356482020
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
5423 Reno Corporate Dr.
Reno, NV, 89511
Phone (775) 329-0873
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.5M
133,697 services
Medicare patients, 2024
762
Average age 74
Drug cost, 2024
$3.7M
2,516 prescriptions
Company payments, 2025
$13K
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sowjanya Reganti was code J1439 (injection, ferric carboxymaltose, 1 mg), 14,250 times for 15 patients. In total Sowjanya Reganti billed 133,697 services in 134 codes, and Medicare paid $2.5M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-05-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 14,250 | 15 | $0.87 | $12K |
| J0897 Injection, denosumab, 1 mg | Office | 10,320 | 55 | $20.49 | $211K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 5,200 | 16 | $44.54 | $232K |
| J9267 Injection, paclitaxel, 1 mg | Office | 3,638 | 11 | $0.08 | $284 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,878 | 51 | $0.09 | $168 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,400 | 42 | $0.69 | $960 |
| 99214 Office E&M - Established | Office | 978 | 485 | $89.79 | $88K |
| 85025 Blood Count | Office | 949 | 398 | $7.55 | $7,162 |
| 36415 Venipuncture Blood Collection | Office | 842 | 384 | $8.61 | $7,249 |
| 80053 Clinical Chemistry | Office | 602 | 285 | $10.23 | $6,160 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 588 | 16 | $0.07 | $42.29 |
| 96375 Injection Administration | Office | 544 | 63 | $11.84 | $6,442 |
| 99215 Office E&M - Established | Office | 507 | 270 | $133.20 | $68K |
| 96413 Chemotherapy Administration | Office | 268 | 85 | $99.49 | $27K |
| Q5111 Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | Office | 264 | 12 | $120.04 | $32K |
By year: 2022 $2.2M for 125,604 services; 2023 $2.6M for 123,286 services; 2024 $2.5M for 133,697 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 949 | 398 | $7.55 | $7,162 |
| 36415 Venipuncture Blood Collection | 842 | 384 | $8.61 | $7,249 |
| 80053 Clinical Chemistry | 602 | 285 | $10.23 | $6,160 |
| 83735 Clinical Chemistry | 85 | 42 | $6.57 | $558 |
| 83615 Clinical Chemistry | 71 | 39 | $5.92 | $420 |
| 84100 Clinical Chemistry | 67 | 38 | $4.65 | $312 |
| 82728 Clinical Chemistry | 50 | 37 | $13.36 | $668 |
| 83540 Clinical Chemistry | 46 | 34 | $6.34 | $292 |
| 83550 Clinical Chemistry | 46 | 35 | $8.57 | $394 |
| 82607 Clinical Chemistry | 38 | 34 | $14.39 | $547 |
Medicare prescription drug claims, 2024
In 2024, the drug Sowjanya Reganti prescribed most often to Medicare patients was Anastrozole, with 1,017 prescriptions and refills. In total Sowjanya Reganti wrote 2,516 Medicare prescriptions that cost $3.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 1,017 | 2,939 | 311 | $33K |
| Alendronate Sodium Generic | 392 | 848 | 107 | $3,350 |
| Letrozole Generic | 163 | 435 | 51 | $5,054 |
| Tamoxifen Citrate Generic | 122 | 334 | 39 | $4,126 |
| Exemestane Generic | 61 | 161 | 25 | $8,739 |
| Verzenio Abemaciclib | 44 | 44 | Under 11 | $637K |
| Hydroxyurea Generic | 41 | 86 | Under 11 | $1,244 |
| Acyclovir Generic | 35 | 49 | Under 11 | $647 |
| Xgeva Denosumab | 32 | 34 | Under 11 | $99K |
| Jakafi Ruxolitinib Phosphate | 31 | 31 | Under 11 | $359K |
| Gabapentin Generic | 28 | 48 | Under 11 | $281 |
| Prolia Denosumab | 24 | 143 | 16 | $39K |
| Fulvestrant Generic | 23 | 23 | Under 11 | $4,604 |
| Palonosetron Hcl Generic | 21 | 21 | Under 11 | $1,243 |
| Diphenhydramine Hcl Generic | 18 | 18 | Under 11 | $59.26 |
Brand drugs: 375 claims; generic drugs: 2,141 claims; opioid claims: 19.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sowjanya Reganti $13K ($13K in general payments such as food, travel and fees) from 21 companies. The largest payer was Daiichi Sankyo Inc. with $9,890.
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. 4568.T | 6 | $9,890 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $2,036 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $153 |
| E.R. Squibb & Sons, L.L.C. BMY | 4 | $125 |
| Pfizer Inc. PFE | 4 | $84.07 |
| Edwards Lifesciences Corporation EW | 3 | $83.23 |
| SpringWorks Therapeutics, Inc. | 2 | $54.92 |
| Exelixis Inc. EXEL | 2 | $48.69 |
| Array Biopharma Inc PFE | 1 | $30.17 |
| Syndax Pharmaceuticals, Inc. SNDX | 1 | $28.28 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.